Trial Profile
Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Irinotecan (Primary) ; Vincristine (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2021 Results (n=35) assessing health-related quality of life and the benefit-risk in quality-adjusted survival published in the Medicine
- 01 Jul 2021 Results (n=41)assessing the safety and efficacy of anlotinib, vincristine, andirinotecan (AVI) in patients with advanced EWS published in the Oncologist
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress